Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulation, Reimbursement Notes From Turkey

This article was originally published in PharmAsia News

Executive Summary

A PharmAsia News update shows Turkey has set a target to domestically manufacture 60% of the drug products used annually and 20% of medical device and equipment by an unspecified timeframe. The government also moved to offer more support into R&D for high-value biopharmaceutical products and sent a large ministerial delegation to the annual Bio Conference in San Diego as a signal of how important the sector is to its public health programs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC087568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel